When to Discuss Prostate Cancer Screening With Average-Risk Men.
作者信息
Gulati Roman, Carlsson Sigrid V, Etzioni Ruth
机构信息
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
出版信息
Am J Prev Med. 2021 Aug;61(2):294-298. doi: 10.1016/j.amepre.2021.02.024. Epub 2021 May 6.
Abstract
摘要
相似文献
1
When to Discuss Prostate Cancer Screening With Average-Risk Men.何时与平均风险男性讨论前列腺癌筛查
Am J Prev Med. 2021 Aug;61(2):294-298. doi: 10.1016/j.amepre.2021.02.024. Epub 2021 May 6.
2
Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men.种族、遗传的西非血统以及前列腺特异性抗原在前列腺癌前瞻性筛查高危男性中的预测作用
Cancer Prev Res (Phila). 2009 Mar;2(3):244-50. doi: 10.1158/1940-6207.CAPR-08-0150. Epub 2009 Feb 24.
3
Physician Consultations, Prostate Cancer Knowledge, and PSA Screening of African American Men in the Era of Shared Decision-Making.共同决策时代非裔美国男性的医生咨询、前列腺癌知识与前列腺特异性抗原筛查
Am J Mens Health. 2018 Jul;12(4):751-759. doi: 10.1177/1557988318763673. Epub 2018 Apr 16.
4
Disparities in prostate cancer in African American men: what primary care physicians can do.非裔美国男性的前列腺癌差异：初级保健医生能做什么。
Cleve Clin J Med. 2012 May;79(5):313-20. doi: 10.3949/ccjm.79a.11001.
5
Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era.当代美国黑人男性前列腺特异性抗原筛查的决定因素。
J Urol. 2016 Apr;195(4 Pt 1):913-8. doi: 10.1016/j.juro.2015.11.023. Epub 2015 Nov 17.
6
Prostate cancer in black men: Is it time for personalized screening approaches?黑人男性的前列腺癌：是时候采用个性化筛查方法了吗？
Cancer. 2017 Jun 15;123(12):2203-2205. doi: 10.1002/cncr.30685. Epub 2017 Apr 24.
7
Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening.种族、家族史和前列腺特异抗原在前列腺癌早期筛查中的相对价值。
J Urol. 2014 Sep;192(3):724-8. doi: 10.1016/j.juro.2014.03.032. Epub 2014 Mar 15.
8
Prostate cancer screening in African American men: a review of the evidence.非裔美国男性的前列腺癌筛查：证据回顾。
J Natl Cancer Inst. 2024 Jan 10;116(1):34-52. doi: 10.1093/jnci/djad193.
9
Prostate Cancer Foundation Screening Guidelines for Black Men in the United States.美国黑人男性前列腺癌基金会筛查指南
NEJM Evid. 2024 May;3(5):EVIDoa2300289. doi: 10.1056/EVIDoa2300289. Epub 2024 Apr 23.
10
African Americans' Perceptions of Prostate-Specific Antigen Prostate Cancer Screening.非裔美国人对前列腺特异性抗原前列腺癌筛查的看法。
Health Educ Behav. 2015 Aug;42(4):539-44. doi: 10.1177/1090198114566453. Epub 2015 Jan 23.
引用本文的文献
1
Health inequity drives disease biology to create disparities in prostate cancer outcomes.健康不平等导致疾病生物学产生前列腺癌结果的差异。
J Clin Invest. 2022 Feb 1;132(3). doi: 10.1172/JCI155031.
本文引用的文献
1
The American Cancer Society's Facts & Figures: 2020 Edition.美国癌症协会《2020年事实与数据》版
J Adv Pract Oncol. 2020 Mar;11(2):135-136. doi: 10.6004/jadpro.2020.11.2.1. Epub 2020 Mar 1.
2
Reconsidering the Trade-offs of Prostate Cancer Screening.重新审视前列腺癌筛查的权衡取舍。
N Engl J Med. 2020 Jun 18;382(25):2465-2468. doi: 10.1056/NEJMsb2000250.
3
"PSA Surveillance in the Septuagenarian": A Proposed New Terminology for Clinical Follow-up to Assess Risk of Prostate Cancer in Men Aged 70 Years and Older.“70 岁及以上男性前列腺特异性抗原（PSA）监测：一种评估前列腺癌风险的临床随访新术语”。
Eur Urol. 2020 Aug;78(2):136-137. doi: 10.1016/j.eururo.2020.03.028. Epub 2020 Apr 6.
4
MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.MRI 靶向、系统和联合活检在前列腺癌诊断中的应用。
N Engl J Med. 2020 Mar 5;382(10):917-928. doi: 10.1056/NEJMoa1910038.
5
Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer.基于前列腺特异性抗原的风险分层前列腺癌筛查的终生获益和危害。
J Natl Cancer Inst. 2020 Oct 1;112(10):1013-1020. doi: 10.1093/jnci/djaa001.
6
Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels.过度诊断与因前列腺特异抗原水平处于中间值而进行的反射性检测挽救的生命。
J Natl Cancer Inst. 2020 Apr 1;112(4):384-390. doi: 10.1093/jnci/djz127.
7
Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.纳入患者合并症的基于筛查的前列腺癌过度诊断的个体化风险：评估与交流。
J Urol. 2019 Nov;202(5):936-943. doi: 10.1097/JU.0000000000000346. Epub 2019 Oct 9.
8
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.欧洲前列腺癌筛查随机研究的 16 年随访。
Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.
9
Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.前列腺癌发病率和死亡率的延长随访研究：前列腺、肺、大肠和卵巢随机癌症筛查试验的参与者。
BJU Int. 2019 May;123(5):854-860. doi: 10.1111/bju.14580. Epub 2018 Nov 2.
10
Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening.美国 2018 年癌症筛查：对当前美国癌症协会指南和癌症筛查中当前问题的综述。
CA Cancer J Clin. 2018 Jul;68(4):297-316. doi: 10.3322/caac.21446. Epub 2018 May 30.
Zotero 插件